Improving quality in prostate cancer care through personalised diagnostic testing – Educational project 2025/2026
Developed in collaboration with Pfizer
Personalised diagnostic tests are essential in tailoring prostate cancer care, leveraging unique molecular features such as gene alterations and protein expression for treatment selection and prognosis. SPCC will host a closed task force on 12th June 2025, followed by a manuscript that will summarise key findings on the role of molecular testing, imaging, and pharmacogenomics in improving disease management and patient outcomes.